These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study. Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Knecht W; Henseling J; Löffler M Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902 [TBL] [Abstract][Full Text] [Related]
10. Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia. Houshmand M; Vitale N; Orso F; Cignetti A; Molineris I; Gaidano V; Sainas S; Giorgis M; Boschi D; Fava C; Passoni A; Gai M; Geuna M; Sora F; Iurlo A; Abruzzese E; Breccia M; Mulas O; Caocci G; Castagnetti F; Taverna D; Oliviero S; Pane F; Lolli ML; Circosta P; Saglio G Cell Death Dis; 2022 Jun; 13(6):576. PubMed ID: 35773274 [TBL] [Abstract][Full Text] [Related]
11. Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives. Zhang L; Zhang J; Wang J; Ren C; Tang P; Ouyang L; Wang Y Eur J Med Chem; 2022 Mar; 232():114176. PubMed ID: 35151222 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and SAR of indazole and benzoisoxazole containing 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists. Zhang X; Hufnagel H; Hou C; Opas E; McKenney S; Crysler C; O'Neill J; Johnson D; Sui Z Bioorg Med Chem Lett; 2011 Oct; 21(20):6042-8. PubMed ID: 21917454 [TBL] [Abstract][Full Text] [Related]
13. Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy. Lolli ML; Sainas S; Pippione AC; Giorgis M; Boschi D; Dosio F Recent Pat Anticancer Drug Discov; 2018; 13(1):86-105. PubMed ID: 29119937 [TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase. Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542 [TBL] [Abstract][Full Text] [Related]
16. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. Sainas S; Pippione AC; Lupino E; Giorgis M; Circosta P; Gaidano V; Goyal P; Bonanni D; Rolando B; Cignetti A; Ducime A; Andersson M; Järvå M; Friemann R; Piccinini M; Ramondetti C; Buccinnà B; Al-Karadaghi S; Boschi D; Saglio G; Lolli ML J Med Chem; 2018 Jul; 61(14):6034-6055. PubMed ID: 29939742 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium. Chen SF; Perrella FW; Behrens DL; Papp LM Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622 [TBL] [Abstract][Full Text] [Related]
18. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Knecht W; Löffler M Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339 [TBL] [Abstract][Full Text] [Related]